




Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/820,790	03/30/2001	Wei Shao	CL001204

CELERA GENOMICS CORPORATION
45 West Gude Dr. C2-4#20
Rockville, MD 20850



Date Mailed: 02/24/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: The Office Of Initial Patent Examination.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

nu

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: WEI SHAO et al.

Art Unit:

Serial No. 09/820,790

Examiner:

Filed: March 30, 2001

Atty. Docket: CL001204

For: ISOLATED HUMAN KINASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN
KINASE PROTEINS, AND USES THEREOF

**Submission Of Substitute Sequence Listing
Under 37 CFR § 1.821(a)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing. The Sequence Listing includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

Date: March 24, 2003

By: 

Justin D. Karjala, Reg. 43,704

Celera Genomics
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084